Abstracts tagged "methotrexate (MTX) and prednisolone"

Abstract Number: 2396 • 2018 ACR/ARHP Annual Meeting
Reduction in the Utilization of Prednisone and/or Methotrexate Following the Initiation of Etanercept in Pediatric Patients
Majed M M Khraishi¹, Brad Millson², John Woolcott³, Lisa Marshall⁴ and Heather Jones⁴, ¹Memorial University of Newfoundland, St John's, NF, Canada, ²IQVIA, Kanata, ON, Canada, ³Global Outcomes & Evidence, Pfizer, Collegeville, PA, ⁴Pfizer, Collegeville, PA
Background/Purpose: In Canada, the pediatric indications of etanercept (ETN) are active ankylosing spondylitis (AS), plaque psoriasis (PsO) and moderate to severely active juvenile idiopathic arthritis…
Abstract Number: 2473 • 2012 ACR/ARHP Annual Meeting
A Randomized Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine Versus Prednisone Plus Methotrexate
Nicolino Ruperto¹, Angela Pistorio², Sheila Oliveira³, Rubén J. Cuttica⁴, Angelo Ravelli¹, Michel Fischbach⁵, Stefan Hagelberg¹, Tadej Avcin⁶, Emanuel Cheuret¹, Fabrizia Corona⁷, Gerard Couillault¹, Frank Dressler¹, Valeria Gerloni¹, Gary Sterba Sr.¹, Francesco Zulian¹, Maria Teresa Apaz¹, Adriana Cespedes-Cruz¹, Rolando Cimaz¹, Fabrizio De Benedetti⁸, Pierre Quartier¹, Ricardo Russo¹, Nico Wulffraat¹, Simona Angioloni¹ and Alberto Martini⁹, ¹Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ²PRINTO, Genoa, Italy, ³Istituto Giannina Gaslini, Pediatria II, Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO) Coordinating Center, Genoa, Italy, Genova, Italy, ⁴Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁵Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, ⁶The Ljubljana University Medical Centre, Pediatric Clinic, Ljubljana, Slovenia, ⁷Reumatologia Pediatrica, Paediatric Department University of Milano, Milano, Italy, ⁸IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ⁹Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH
Background/Purpose: Data regarding the safety and efficacy of treatment regimens for juvenile dermatomyositis(JDM) tends to be from anecdotal, small, uncontrolled, non-randomized case series. This randomized…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].